ASAmelia-Naomi Sabo

Amelia-Naomi Sabo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amelia-Naomi Sabo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Simplifying Busulfan Conditioning in Children: Once Daily vs. Four-Times-Daily IV Dosing in Hematopoietic Cell Transplantation

    by Manon Dzedzej, Charlotte Nazon, Guillaume Becker, Amelia-Naomi Sabo, Véronique Kemmel, Catherine Paillard

    Background/Objectives: Busulfan is a key component of conditioning regimens for hematopoietic cell transplantation (HCT). Although once-daily (OD) intravenous administration is logistically advantageous over the conventional four-times-daily (QID) schedule, concerns remain regarding a potential increased risk of hepatic veno-occlusive disease (VOD or sinusoidal obstruction syndrome/SOS), particularly in children. Methods: We retrospectively reviewed all pediatric patients receiving busulfan-based conditioning with therapeutic drug monitoring (TDM) at a single center (January 2015–December 2024). The primary analysis compared VOD/SOS incidence within 100 days post-HCT, diagnosed by revised EBMT criteria, between the OD and allogeneic QID groups (QIDallo). Secondary analyses evaluated VOD/SOS severity, busulfan pharmacokinetic (PK) parameters, and clinical risk factors and compared the OD and total QID groups. Results: One hundred HCT procedures were included (36 OD, 64 QIDtot including 39 QIDallo). There was no statistically significant between-group difference (p = 0.777 for OD/QIDallo and p = 0.960 for OD/QIDtot), including after adjustment for age and disease. OD yielded higher Cmax than QIDallo and QID (p < 0.001), but PK parameters were not associated with VOD/SOS. Independent risk factors were age ≤5 years (p = 0.001) and thalassemia (p = 0.035). Conclusions: In this pediatric cohort, PK-guided OD busulfan was not associated with an increased VOD/SOS risk despite higher Cmax, supporting its use in children when TDM is implemented. Young age and thalassemia remained the principal determinants of VOD/SOS.

  • Open Access

    The Hydroxyurea Absorption Phenotype: A Key PK/PD Determinant in Sickle Cell Disease Treatment

    by Amelia-Naomi Sabo, Charlotte Nazon, Catherine Paillard, Véronique Kemmel

    Background/Objectives: Hydroxyurea (HU), a cornerstone treatment for sickle cell disease (SCD), exhibits marked interindividual pharmacokinetic/pharmacodynamic (PK/PD) variability that remains poorly understood. This study aimed to establish a population PK model using OPTIMDREP randomized trial data (NCT06464458), quantify parameter variability, and identify covariates influencing HU PK and hematological response. Methods: Plasma sampling data from 22 SCD patients (20 pediatric and 2 adult patients; median age: 11.2 years [range: 2.5–35.7]) on once-daily oral HU underwent a non-compartmental analysis (NCA) followed by nonlinear mixed-effects modeling (MonolixSuite®). PK variability covariates and PK/PD correlations with the mean corpuscular volume (MCV), reticulocytes, fetal hemoglobin percentage (HbF%) and neutrophils were investigated. Results: NCA identified two absorption phenotypes (rapid/slow), with higher maximum concentration values observed for rapid (36.5 ± 18.8 mg/L) compared to slow (22.3 ± 8.4 mg/L) (p = 0.0013) profiles but not statistically different total exposures, apparent clearances (Cl/F) or volumes of distribution (Vd/F). The population approach identified the one-compartment model (first-order absorption and linear elimination) and confirmed the absorption phenotype as the key absorption rate (ka) covariate (9.93 vs. 1.36 h−1), explaining half of the ka interindividual variability (IIV). The median-normalized body weight was retained for both the Cl/F and Vd/F, as it significantly reduced the objective function value. No hematological parameter was correlated to PK parameters. However, rapid absorbers showed a superior response on the MCV (Δ = 9.1 fL, p < 0.0001), reticulocytes (Δ = −42.2 G/L, p < 0.01), and HbF% trend (Δ = 2.8%, p = 0.0835) but not on neutrophil counts (p = 0.8757). Conclusions: The absorption phenotype, a novel covariate explaining half of the ka IIV, predicts a superior erythropoietic response without toxicity in SCD patients. These findings support absorption phenotype integration into PK-guided dosing algorithms to optimize early-response biomarkers and personalize HU therapy.


  • Étude des effets des liquides pour cigarette électronique et de la cigarette classique chez l’Homme, la souris et sur un modèle de barrière alvéolo-capillaire

    by Amélia-Naomi Sabo

    Les e-cigarettes (e-cig) n’ont pas démontré leur efficacité et leur tolérance, en partie à cause d’un large choix de liquides (eL) contenant des véhicules, des arômes et de la nicotine à différentes concentrations, complexifiant les études scientifiques. Les travaux présentés ici concernent 3 niveaux d’analyse. Chez l’Homme, les résultats de l’essai clinique VAPexp’AIR sont les premiers à montrer que la formulation du eL influence la masse de nicotine inhalée et ses paramètres pharmacocinétiques. Chez la souris, un modèle de BPCO post-tabagique a été développé présentant des caractéristiques pathologiques telles que le recrutement des cellules immunitaires dans les voies aériennes inférieures associé à de l’emphysème pulmonaire. Ce modèle sera utilisé comme témoin lors de l’exposition à la e-cig. In vitro, l’exposition d’un modèle de barrière alvéolo-capillaire aux principaux composants des e-L a montré des effets néfastes sur l’intégrité de la barrière, l’inflammation, le stress oxydant et la mort cellulaire, pour les principaux composants des e-L et leurs mélanges. La présence d’arômes mentholé et fruité, ainsi que de nicotine dans la composition des e-L semble empirer les observations.

  • Open Access

    Delayed Drug–Drug Interaction Between Antiviral Drugs and Tacrolimus in a Pancreatic Islet Transplant Recipient With SARS-CoV-2 Pneumonia

    by Amelia-Naomi Sabo, Sibylle Cunat, Véronique Kemmel

    Background: PAXLOVID (nirmatrelvir and ritonavir) and VEKLURY (remdesivir) are the first- and second-line antivirals administered to adult patients at risk of severe forms of SARS-CoV-2 infection (COVID-19), such as transplant recipients. As this specific population requires lifelong immunosuppressive treatments, the administration of antivirals with cytochrome P450-modulating properties exposes patients to a high risk of drug–drug interactions (DDI). Case Presentation: A 72-year-old male patient who underwent a pancreatic islet transplant experienced DDI between antiviral treatment and tacrolimus during the management of SARS-CoV-2 pneumonia. The patient received a single dose of nirmatelvir/ritonavir followed by a single dose of remdesivir. Tacrolimus treatment was interrupted for the duration of the antiviral treatment, and the concentration of tacrolimus was within the target range for this patient. Once antiviral treatment was stopped, tacrolimus was reintroduced at the initial dose. On day 6, the patient presented with clinical and biological parameters consistent with a tacrolimus overdose. A trough concentration 18 times higher than the therapeutic target was found, prompting tacrolimus to be discontinued for 9 days and reintroduced at a lower dose, followed by a gradual increase based on therapeutic drug monitoring to the initial dose. Clinical and biological parameters gradually returned to baseline levels. Conclusions: Management of DDI between tacrolimus and anti-SARS-CoV-2 drugs requires a substantial therapeutic intervention and close therapeutic drug monitoring during and for several days after antiviral treatment.


  • Flavoured and nicotine-containing e-liquids impair homeostatic properties of an alveolar-capillary cell model

    by Amelia-Naomi Sabo, Emma Filaudeau, Sylvia Da Silva, Guillaume Becker, Laurent Monassier, Véronique Kemmel


  • Open Access

    Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?

    by Guillaume Becker, Sylvia Da Silva, Amelia-Naomi Sabo, Maria Cristina Antal, Véronique Kemmel, Laurent Monassier

    Serotonin affects many functions in the body, both in the central nervous system (CNS) and the periphery. However, its effect on the blood–brain barrier (BBB) in separating these two worlds has been scarcely investigated. The aim of this work was to characterize the serotonin receptor 5-HT4 in the hCMEC/D3 cell line, in the rat and the human BBB. We also examined the effect of prucalopride, a 5-HT4 receptor agonist, on the permeability of the hCMEC/D3 in an in vitro model of BBB. We then confirmed our observations by in vivo experiments. In this work, we show that the 5-HT4 receptor is expressed by hCMEC/D3 cells and in the capillaries of rat and human brains. Prucalopride increases the BBB permeability by downregulating the expression of the tight junction protein, occludin. This effect is prevented by GR113808, a 5-HT4 receptor antagonist, and is mediated by the Src/ERK1/2 signaling pathway. The canonical G-protein-dependent pathway does not appear to be involved in this phenomenon. Finally, the administration of prucalopride increases the diffusion of Evans blue in the rat brain parenchyma, which is synonymous with BBB permeabilization. All these data indicate that the 5-HT4 receptor contributes to the regulation of BBB permeability.


  • Open Access

    Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

    by Amelia-Naomi Sabo, Sarah Jannier, Guillaume Becker, Jean-Marc Lessinger, Natacha Entz-Werlé, Véronique Kemmel

    Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM. In the RAPIRI phase I trial, the combination sirolimus + irinotecan was evaluated as a new treatment for refractory pediatric cancers. Blood sampling at first sirolimus intake (D1) and at steady state (D8), followed by LC/MS2 analysis, was used to develop a population pharmacokinetic model (Monolix® software). A mono-compartmental model with first-order absorption and elimination best fit the data. The only covariate retained for the final model was “body surface area” (D1 and D8). The model also demonstrated that 1.5 mg/m2 would be the recommended sirolimus dose for further studies and that steady-state TDM is necessary to adjust the dosing regimen in atypical profiles (36.4% of the population). No correlation was found between sirolimus trough concentrations and efficacy and/or observed toxicities. The study reveals the relevance of sirolimus TDM in pediatric oncology as it is needed in organ transplantation.


  • Open Access

    Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach

    by Charlotte Nazon, Amelia-Naomi Sabo, Guillaume Becker, Jean-Marc Lessinger, Véronique Kemmel, Catherine Paillard

    Background: Hydroxyurea (HU) is a FDA- and EMA-approved drug that earned an important place in the treatment of patients with severe sickle cell anemia (SCA) by showing its efficacy in many studies. This medication is still underused due to fears of physicians and families and must be optimized. Methods: We analyzed our population and identified HU pharmacokinetic (PK) parameters in order to adapt treatment in the future. Working with a pediatric population, we searched for the most indicative sampling time to reduce the number of samples needed. Results: Nine children treated by HU for severe SCA were included for this PK study. HU quantification was made using a validated gas chromatography/mass spectrometry (GC/MS) method. Biological parameters (of effectiveness and compliance) and clinical data were collected. None of the nine children reached the therapeutic target defined by Dong et al. as an area under the curve (AUC) = 115 h.mg/L; four patients were suspected to be non-compliant. Only two patients had an HbF over 20%. The 2 h sample was predictive of the medication exposure (r2 = 0.887). Conclusions: It is urgent to be more efficient in the treatment of SCA, and pharmacokinetics can be an important asset in SCA patients.